<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452189</url>
  </required_header>
  <id_info>
    <org_study_id>17-00963</org_study_id>
    <nct_id>NCT03452189</nct_id>
  </id_info>
  <brief_title>The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome</brief_title>
  <official_title>The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if multiple doses of vancomycin over the course of
      3 months will perturb the intestinal flora (microbiome) and result in reduced serum
      concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the
      study will permit investigators to assess the variability of serum uremic retention solute
      concentrations with and without antibiotic over a three-month period.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized double-blinded placebo-controlled crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Concentration Measure of Indoxyl Sulphate (IS)-Pre Dialysis</measure>
    <time_frame>Day 0; Weekly for 1 Month; Monthly for 2 Months</time_frame>
    <description>Plasma concentrations of IS were measured by HPLC (high pressure liquid chromatography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration Measure Indoxyl Sulphate (IS) Post Dialysis</measure>
    <time_frame>Day 0; Weekly for 1 Month; Monthly for 2 Months</time_frame>
    <description>Plasma concentrations of IS were measured by HPLC (high pressure liquid chromatography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration Measure P-Cresyl Sulphate (PCS) Pre Dialysis</measure>
    <time_frame>Day 0; Weekly for 1 Month; Monthly for 2 Months</time_frame>
    <description>Plasma concentrations of P-Cresyl Sulphate (PCS) were measured by HPLC (high pressure liquid chromatography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration Measure P-Cresyl Sulphate (PCS) Post Dialysis</measure>
    <time_frame>Day 0; Weekly for 1 Month; Monthly for 2 Months</time_frame>
    <description>Plasma concentrations of P-Cresyl Sulphate (PCS) were measured by HPLC (high pressure liquid chromatography</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>250mg of oral vancomycin First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After 3 months, initial experimental group will be switched to placebo for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After three months, the control group will be crossed over to weekly oral vancomycin (250mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Oral vancomycin 250mg capsules</description>
    <arm_group_label>250mg of oral vancomycin First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
    <other_name>vancomycin hydrochloride capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Pills distributed by Research Pharmacy labeled &quot;placebo.&quot;</description>
    <arm_group_label>250mg of oral vancomycin First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable chronic kidney disease on hemodialysis with a fistula or an AV
             graft.

        Exclusion Criteria:

          -  Antibiotics received within the last 3 months;

          -  recent diarrhea

          -  known allergy to vancomycin

          -  history of C. difficile infection

          -  elevation of white blood cell count or fever within one week of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome Lowenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Chang</last_name>
    <phone>212 263 7439</phone>
    <email>michelle.chang@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Chang</last_name>
      <phone>212-263-7439</phone>
      <email>michelle.lowenstein@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Jerome Lowenstain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

